Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty
- 30 September 1995
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 130 (3) , 658-665
- https://doi.org/10.1016/0002-8703(95)90303-8
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Length of Hospital Stay and Complications After Percutaneous Transluminal Coronary AngioplastyCirculation, 1995
- Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.Circulation, 1994
- Lesion morphology and coronary angioplasty: Current experience and analysisJournal of the American College of Cardiology, 1992
- Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group.Circulation, 1990
- Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.Circulation, 1990
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981New England Journal of Medicine, 1988
- Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty.Circulation, 1988
- In-hospital cardiac mortality after acute closure after coronary angioplasty: Analysis of risk factors from 8,207 proceduresJournal of the American College of Cardiology, 1988
- Nonoperative Dilatation of Coronary-Artery StenosisNew England Journal of Medicine, 1979